The rise in circulating EPA (20:5n-3) upon provision of supplemental DHA (22:6n-3) has long been assumed to be due to retroconversion—the synthesis of EPA from DHA. In their contribution to the Journal, “Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial,” Richard Bazinet, Adam Metherel, and coworkers at the University of Toronto elegantly show that it is instead the sparing of EPA from metabolism into other products that causes the observed rise in EPA (20:5n-3) (1). Exploiting differences in natural carbon isotope ratios and high-precision measurements, these authors show that EPA is converted to DHA but not the other way round...[sign in required on website to read full article]
Medical opinion and guidance should always be sought for any symptoms that might possibly reflect a known or suspected disease, disorder or medical condition. Information provided on this website (or by FAB Research via any other means) does not in any way constitute advice on the treatment of any medical condition formally diagnosed or otherwise.